基于网络药理学与实验验证解析热毒宁注射液治疗COVID-19的新机制
本研究先在Vero E6细胞中开展抗SARS-CoV-2实验,再以网络药理学联合分子对接预测热毒宁注射液治疗COVID-19的机制,并用蛋白质印迹与细胞因子芯片验证。结果显示热毒宁可调控ACE2、Mpro、PLP及MAPK、PKC、p65 NF-κB等,影响细胞因子水平、减轻炎症并表现解热活性。
要点
- 热毒宁注射液在Vero E6细胞中显示抗SARS-CoV-2活性。
- 其机制可能涉及调控MAPK、PKC与p65 NF-κB,降低炎症与细胞因子水平。
- 网络药理学预测其可作用于ACE2、Mpro、PLP等靶点。
核心结论
- 热毒宁注射液可调控COVID-19相关的ACE2、Mpro和PLP。
- 其治疗COVID-19的潜在机制可能与调控细胞因子水平与炎症、并通过调节MAPKs、PKC和p65核因子NF-κB表达发挥解热活性有关。
研究设计与样本
- 研究先在Vero E6细胞中进行抗SARS-CoV-2实验。
- 随后采用网络药理学联合分子对接探索热毒宁注射液治疗COVID-19的潜在机制。
- 最后用蛋白质印迹和细胞因子芯片验证预测结果。
主要发现
- 热毒宁注射液半数毒性浓度CC50(稀释比)=1:1280,CC50=2.031 mg生药/mL(0.047 mg固含物/mL)。
- 半数有效浓度EC50(稀释倍数)=1:25140.3,EC50=103.420 μg生药/mL(2.405 μg固含物/mL)。
- 热毒宁注射液主要调控碳酸酐酶(CAs)、基质金属蛋白酶(MMPs)等靶点及PI3K/AKT、MAPK、叉头框O和T细胞受体信号通路以减少肺损伤。
- 验证显示热毒宁注射液可有效抑制MAPKs、PKC和p65核因子-κB的过表达。
- 该注射液可影响细胞因子水平、减轻炎症并表现解热活性。
关键数值与推荐
- 在Vero E6细胞中,热毒宁注射液CC50(稀释比)=1:1280,CC50=2.031 mg生药/mL(0.047 mg固含物/mL)。
- 在Vero E6细胞中,热毒宁注射液EC50(稀释倍数)=1:25140.3,EC50=103.420 μg生药/mL(2.405 μg固含物/mL)。
临床怎么用
- 热毒宁注射液已被《新型冠状病毒肺炎诊疗方案》推荐用于治疗COVID-19。
- 本研究的机制结果提示其可能通过抗炎、调节细胞因子与解热途径减轻肺损伤,可供临床辨证用药时参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Reduning injection (RDNI) is a patented Traditional Chinese medicine that contains three Chinese herbal medicines, respectively are the dry aboveground part of Artemisia annua L., the flower of Lonicera japonica Thunb., and the fruit Gardenia jasminoides J.Ellis. RDNI has been recommended for treating Coronavirus Disease 2019 (COVID-19) in the "New Coronavirus Pneumonia Diagnosis and Treatment Plan". AIM OF THE STUDY: To elucidate and verify the underlying mechanisms of RDNI for the treatment of COVID-19. METHODS: This study firstly performed anti-SARS-CoV-2 experiments in Vero E6 cells. Then, network pharmacology combined with molecular docking was adopted to explore the potential mechanisms of RDNI in the treatment for COVID-19. After that, western blot and a cytokine chip were used to validate the predictive results. RESULTS: We concluded that half toxic concentration of drug CC50 (dilution ratio) = 1:1280, CC50 = 2.031 mg crude drugs/mL (0.047 mg solid content/mL) and half effective concentration of drug (EC50) (diluted multiples) = 1:25140.3, EC50 = 103.420 μg crude drugs/mL (2.405 μg solid content/mL). We found that RDNI can mainly regulate targets like carbonic anhydrases (CAs), matrix metallopeptidases (MMPs) and pathways like PI3K/AKT, MAPK, Forkhead box O s and T cell receptor signaling pathways to reduce lung damage. We verified that RDNI could effectively inhibit the overexpression of MAPKs, PKC and p65 nuclear factor-κB. The injection could also affect cytokine levels, reduce inflammation and display antipyretic activity. CONCLUSION: RDNI can regulate ACE2, Mpro and PLP in COVID-19. The underlying mechanisms of RDNI in the treatment for COVID-19 may be related to the modulation of the cytokine levels and inflammation and its antipyretic activity by regulating the expression of MAPKs, PKC and p65 nuclear factor NF-κB.
引用
- Jia S, Luo H, Liu X, et al. Dissecting the novel mechanism of reduning injection in treating Coronavirus Disease 2019 (COVID-19) based on network pharmacology and experimental verification. J Ethnopharmacol. 2021. PMID: 33485971. doi:10.1016/j.jep.2021.113871
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。